Allergy Therapeutics plc (LON:AGY)‘s stock had its “buy” rating reissued by analysts at Panmure Gordon in a research report issued on Wednesday. They currently have a GBX 53 ($0.66) price objective on the stock. Panmure Gordon’s price objective would suggest a potential upside of 153.89% from the company’s previous close.
Other analysts have also recently issued research reports about the stock. Numis Securities Ltd reiterated a “buy” rating and set a GBX 37 ($0.46) price target on shares of Allergy Therapeutics plc in a research note on Monday, October 10th. Stifel Nicolaus reiterated a “buy” rating and set a GBX 72 ($0.90) price target on shares of Allergy Therapeutics plc in a research note on Friday, July 8th.
Allergy Therapeutics plc (LON:AGY) traded down 1.76% during mid-day trading on Wednesday, hitting GBX 20.50. 88,104 shares of the stock were exchanged. The company has a 50-day moving average price of GBX 22.35 and a 200-day moving average price of GBX 21.26. Allergy Therapeutics plc has a one year low of GBX 17.25 and a one year high of GBX 32.60. The company’s market cap is GBX 120.78 million.
In other news, insider Nicolas Wykeman bought 150,000 shares of Allergy Therapeutics plc stock in a transaction dated Tuesday, September 27th. The stock was bought at an average price of GBX 18 ($0.22) per share, for a total transaction of £27,000 ($33,733.13). Also, insider Peter Jensen bought 30,000 shares of Allergy Therapeutics plc stock in a transaction dated Thursday, September 29th. The stock was purchased at an average price of GBX 19 ($0.24) per share, with a total value of £5,700 ($7,121.44).